Cargando…
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
It is striking that all marketed SARS-CoV-2 vaccines are developed for intramuscular administration designed to produce humoral and cell mediated immune responses, preventing viremia and the COVID-19 syndrome. They have a high degree of efficacy in humans (70–95%) depending on the type of vaccine. H...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099545/ https://www.ncbi.nlm.nih.gov/pubmed/33964339 http://dx.doi.org/10.1016/j.ijpharm.2021.120686 |